Biocardia announces cardiamp heart failure pivotal trial continues with first patient randomized in covid-19 era

San carlos, calif., june 29, 2020 (globe newswire) -- biocardia®, inc. , (otc: bcda), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the company has resumed cases in the cardiamp heart failure trial. the first patient procedure completed since elective procedures were paused due to covid-19 took place at morton plant hospital in clearwater, florida this month. new consents have also taken place at additional centers.  
BCDA Ratings Summary
BCDA Quant Ranking